Ensuring a fit-for-purpose resource for consumers, clinicians and health services: the updated Osteoarthritis of the Knee Clinical Care Standard

Abstract

Knee osteoarthritis is a prevalent and disabling condition that impacts activities of daily living, participation in work and family roles, and overall quality of life. With population growth and ageing, an increasing number of Australians are living with knee osteoarthritis (over 1.9 million people in 2019, representing 126% growth relative to 1990 numbers).¹ National estimates indicate that knee osteoarthritis is associated with over 59 000 years lived with disability annually, exceeding the disability burden of dementia, stroke or ischaemic heart disease.¹ Knee osteoarthritis also has a major economic impact in Australia, with over $3.5 billion spent annually on osteoarthritis-related hospital admissions² and an estimated productivity loss of $424 billion.³ International clinical guidelines consistently recommend non-surgical modalities as the mainstay of knee osteoarthritis management, with referral for consideration of joint replacement surgery reserved for people with late-stage disease.^4-6 Concerningly, low value care (care that is wasteful, ineffective and/or harmful) persists across the knee osteoarthritis journey. This is often fuelled by misconceptions about osteoarthritis, including inaccurate beliefs around diagnosis and management, that are amenable to change through education and effective communication.⁷

The Australian Commission on Safety and Quality in Health Care has developed a range of Clinical Care Standards. These aim to: (i) support the delivery of evidence-based clinical care for a health condition or procedure; (ii) reduce variation in clinical care across Australia; and (iii) promote shared decision making between health professionals and consumers. Unlike clinical guidelines, Clinical Care Standards do not describe all the components of care. Instead, they encompass a limited set of quality statements that describe the expected care for a health condition or procedure and highlight priorities for quality improvement.

Evidence of low value osteoarthritis care (specifically, high rates of knee arthroscopy among older Australians, with substantial geographic variation)⁸ pointed to the need for the first Clinical Care Standard targeting knee osteoarthritis. In 2017, the Osteoarthritis of the Knee Clinical Care Standard was launched following a comprehensive development process that involved topic experts and consumers, wider stakeholder consultation, and national peak body endorsement. Seven years on, we introduce the updated Osteoarthritis of the Knee Clinical Care Standard and indicator set (available at www.safetyandquality.gov.au/oak-ccs),⁹ which have been carefully revised to ensure alignment with new evidence, contemporary international guidelines, and advances in person-centred care. The updates also target current priorities for improving osteoarthritis care through reducing low value care. In addition to reducing inappropriate arthroscopy, these priorities include reducing unnecessary imaging, opioid prescribing, and unwarranted knee replacement where optimal non-surgical management has not been trialled.

An overview of the updated Osteoarthritis of the Knee Clinical Care Standard is presented in Box 1. While the scope and goals remain similar, there are several key changes and new features. Importantly, the quality statements are intended to apply to all medical practitioners, allied health professionals and nurses who provide knee osteoarthritis care, to promote consistency in assessment, management, and communication. The settings to which the Clinical Care Standard apply are now clearly articulated, with broad applicability to all settings where osteoarthritis care is delivered. These include community and primary healthcare services, Aboriginal and Torres Strait Islander Community Controlled Health Organisations, hospital settings, and private medical clinics.

There is now a stronger focus on clinical diagnosis and avoidance of unnecessary imaging, notably magnetic resonance imaging, computed tomography, and ultrasound. There is a clear stance that in the limited circumstances where imaging is indicated (restricted to suspicion of alternative diagnoses, the presence of atypical features, rapid worsening of symptoms, or where surgery is being considered), erect x-rays are the preferred option. Guidance is provided to help patients understand why imaging may not be beneficial in their circumstances. Highlighting the importance of self-management support, the quality statement on exercise now includes recommendations for physical activity, and a new quality statement on weight management (rather than “weight loss”) and optimal nutrition is included. The updated Clinical Care Standard also places greater emphasis on avoiding opioid analgesics for knee osteoarthritis, given the unfavourable risk–benefit ratio and the secondary role of medicines in ongoing osteoarthritis management.

The updated Osteoarthritis of the Knee Clinical Care Standard is an important tool that can support best practice care for people presenting with suspected knee osteoarthritis. Emphasising the role of clinical diagnosis and with an enhanced focus on physical activity, exercise, weight management and nutrition, the Clinical Care Standard covers the full spectrum of care that should be trialled before consideration of surgery. The addition of cultural safety and equity considerations and clinician communication tips, together with new guides for healthcare services, clinicians and consumers, ensures a contemporary resource with practical value.

The authors declare: support for attendance at Osteoarthritis of the Knee Clinical Care Standard meetings (Dooley, Favorito), research funding unrelated to editorial preparation (Ackerman, Buchbinder, Bunzli, Hunter), employment with the Australian Commission on Safety and Quality in Health Care (Doukas, Bhasale, Holdenson Kimura), payment for lectures, presentations or workshops (Bunzli, Doukas), royalties for UpToDate authorship for an unrelated topic (Buchbinder), consulting fees for pharmaceutical Scientific Advisory Boards (Hunter; Pfizer, Lilly, TLCBio, Novartis), payment for participation in the Therapeutic Guidelines Rheumatology review panel (Dooley), payment as co-Editor-in-Chief, Osteoarthritis and Cartilage journal (Hunter), payment as Editor of the Osteoarthritis section for UpToDate (Hunter), travel support as an invited speaker at scientific conferences (Buchbinder) or to attend international conferences or research meetings (Bunzli), leadership roles with the Board of Pharmacy Specialties (Doukas), Osteoarthritis Research Society International (Hunter) and Australian Orthopaedic Association National Joint Replacement Registry (Vertullo), and Data Safety Monitoring Board participation (Hunter, Vertullo).

This editorial is being published in the following journals: ANZ Journal of Surgery; Australian Journal of General Practice; Internal Medicine Journal; Journal of Medical Imaging and Radiation Oncology; Journal of Physiotherapy; and Medical Journal of Australia. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Any of the citations can be used when citing this article.